NCT03330847: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: BRCA+, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Three cohorts will be studied: 1) BRCA1/2+ TNBC patients 2) TNBC patients with gene mutations in the DNA repair pathway, but not BRCA1/2+, and 3) TNBC patients with no BRCA or DNA repair mutations
Exclusions: Symptomatic uncontrolled brain metastases
https://ClinicalTrials.gov/show/NCT03330847

Comments are closed.

Up ↑